All In Biotech

Drug Trial Radar · NCT07431827

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Oct 26, 2039

Study completion Oct 26, 2039

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • CalderasibDrug

    MK-1084 oral tablet

  • MK-3475ABiological

    Fixed dose coformulated product of hyaluronidase/pembrolizumab administered via SC injection.

  • PlaceboDrug

    Placebo oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS)Time frame: Up to ~11 years

Locations

125 sites in 19 countries. Site status is shown where the registry gives one.

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0306)

    CABA, Argentina · Recruiting

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309)

    CABA, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0310)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Sanatorio Parque ( Site 0311)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Northern Beaches Hospital ( Site 3009)

    Frenchs Forest, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital ( Site 3012)

    Woolloongabba, Queensland, Australia · Recruiting

  • Peninsula University Hospital ( Site 3011)

    Frankston, Victoria, Australia · Recruiting

  • Hospital Alemao Oswaldo Cruz ( Site 0416)

    São Paulo, Brazil · Recruiting

  • PRONUTRIR ( Site 0425)

    Fortaleza, Ceará, Brazil · Recruiting

  • AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0414)

    Vitória, Espírito Santo, Brazil · Recruiting

  • Hospital Madre Teresa ( Site 0420)

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Real Hospital Portugues ( Site 0418)

    Recife, Pernambuco, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0402)

    Porto Alegree, Rio Grande do Sul, Brazil · Recruiting

  • Faculdade de Medicina do ABC ( Site 0415)

    Santo André, São Paulo, Brazil · Recruiting

  • Instituto do Câncer Brasil - Unidade Taubaté ( Site 0424)

    Taubaté, São Paulo, Brazil · Recruiting

  • Moncton Hospital ( Site 0200)

    Moncton, New Brunswick, Canada · Recruiting

  • CIUSSS- saguenay-Lac-Saint-Jean ( Site 0216)

    Chicoutimi, Quebec, Canada · Recruiting

  • Centre Hospitalier de l'Université de Montréal ( Site 0219)

    Montreal, Quebec, Canada · Recruiting

  • Clínica MEDS La Dehesa ( Site 0509)

    Lo Barnechea, Region M. de Santiago, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0501)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión ( Site 0503)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradford Hill ( Site 0508)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Peking University People's Hospital ( Site 2100)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer hospital ( Site 2106)

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital ( Site 2105)

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Three Gorges Hospital ( Site 2138)

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital Of Fujian Medical University ( Site 2123)

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital ( Site 2122)

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center ( Site 2134)

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital ( Site 2115)

    Nanning, Guangxi, China · Recruiting

  • Fourth Hospital Of Hebei Medical University ( Site 2107)

    Hshijiazhuang, Hebei, China · Recruiting

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 2140)

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139)

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital Central South University ( Site 2136)

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital ( Site 2112)

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University ( Site 2121)

    Nanchang, Jiangxi, China · Recruiting

  • Affiliated Cancer Hospital of Shandong First Medical University ( Site 2111)

    Jinan, Shandong, China · Recruiting

  • Shanghai Pulmonary Hospital ( Site 2125)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center ( Site 2137)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital of Fudan University ( Site 2119)

    Shanghai, Shanghai Municipality, China · Recruiting

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.